SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. (QUBT) is trending following its strategic $110 million acquisition of Luminar Semiconductor, a move expected to accelerate its photonic technology roadmap and expand its customer base into defense and aerospace. This development fuels community discussion, with bulls highlighting the potential of its unique room-temperature photonic chips and recent institutional investment, while skeptics point to high valuations and limited near-term revenue as major risks within the broader quantum computing sector.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending due to the accumulating global regulatory approvals for EKTERLY, its innovative oral on-demand hereditary angioedema treatment, with Japan being the latest market. The community is actively discussing the drug's strong initial sales performance and its significant market advantage as the first oral option, fueling optimism for its global commercialization. Analysts are reinforcing bullish sentiment, recognizing the company's trajectory towards profitability and its strategic position within the biotech sector, with many anticipating further upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arlo Technologies, Inc. $ARLO Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC cut its holdings in shares of Arlo Technologies, Inc. (NYSE:ARLO - Free Report) by 9.8% during the third quarter, according to the company in its most recent filing...

Voya Investment Management LLC Purchases 168,248 Shares of Arlo Technologies, Inc. $ARLO

Voya Investment Management LLC lifted its holdings in Arlo Technologies, Inc. (NYSE:ARLO - Free Report) by 160.2% during the 3rd quarter, according to its most recent filing with the Securities...

Is Arlo Technologies (ARLO) Stock Outpacing Its Computer and Technology Peers This Year?

Here is how Arlo Technologies (ARLO) and Lam Research (LRCX) have performed compared to their sector so far this year.

Arlo Technologies, Inc. (NYSE:ARLO) Receives Consensus Rating of "Buy" from Analysts

Arlo Technologies, Inc. (NYSE:ARLO - Get Free Report) has been assigned an average rating of "Buy" from the five research firms that are covering the firm, Marketbeat.com reports. One equities...

Castleark Management LLC Makes New Investment in Arlo Technologies, Inc. $ARLO

Castleark Management LLC bought a new stake in Arlo Technologies, Inc. (NYSE:ARLO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and...

G2 Investment Partners Management LLC Invests $2.21 Million in Arlo Technologies, Inc. $ARLO

G2 Investment Partners Management LLC acquired a new stake in shares of Arlo Technologies, Inc. (NYSE:ARLO - Free Report) during the second quarter, according to the company in its most recent 13F...

StoneCo Stock Up 64.3% in a Year: Buying Opportunity or Risky Timing?

Do STNE's rising profit and a sharper fintech focus fuel investor debate on whether its momentum signals a compelling entry point? Let us find out.

Marshall Wace LLP Buys 792,294 Shares of Arlo Technologies, Inc. $ARLO

Marshall Wace LLP increased its stake in shares of Arlo Technologies, Inc. (NYSE:ARLO - Free Report) by 110.3% in the second quarter, according to the company in its most recent Form 13F filing with...

Divisadero Street Capital Management LP Purchases 1,019,945 Shares of Arlo Technologies, Inc. $ARLO

Divisadero Street Capital Management LP increased its position in Arlo Technologies, Inc. (NYSE:ARLO - Free Report) by 778.6% in the second quarter, according to the company in its most recent Form...

Is Arlo Technologies (ARLO) Outperforming Other Computer and Technology Stocks This Year?

Here is how Arlo Technologies (ARLO) and ASML (ASML) have performed compared to their sector so far this year.

Arlo Technologies, Inc. engages in the provision and development of cloud services artificial intelligence, computer vision analytics, wireless connectivity, and user experience design, and home security. The firm offers security systems, cameras, doorbells, and floodlight. It operates through the following geographical segments: United States, Spain, Ireland, and Other Countries. The company was founded in January 2018 and is headquartered in Carlsbad, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.16	--	--	N/A
Q3 '25	$0.15	$0.16	7.96%	BEAT
Q2 '25	$0.15	$0.17	11.45%	BEAT
Q1 '25	$0.12	$0.15	29.00%	BEAT
Q4 '24	$0.10	$0.10	-4.40%	MISSED

ARLO
Arlo Technologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ARLO News

ARLOArlo Technologies Inc